

On Page 26, Claim 4, amend and add as follows:

A method for preparation of the compound according to claim 3, comprising the step of esterifying ~~or phosphoric esterifying~~ the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with succinic anhydride to obtain the compound of formula II, or the step of phosphoric esterifying the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with POCl<sub>3</sub>, PCl<sub>3</sub>, phosphonate halide, phosphate, phosphite halide, or phosphite to obtain the compound of formula II.

#### AMENDMENTS TO THE SPECIFICATION

On Page 4, line 3, amend to read: wherein R<sub>1</sub> is H, alkyl having 1-4 carbon atom(s), -C(=O)(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H-, wherein n is an integer of 1-4; or ;

On Page 4, line 11 of the PCT publication, *Succinic anhydride* should be replaced with 4-Oxo-butyric acid.

On Page 5, line 11, the following paragraphs should be inserted after the chemical structure located on the top of the page:

The present invention provides a method for preparation of the compound of formula I, comprising the step of reacting the first lead compound triptolide with POCl<sub>3</sub>, PCl<sub>3</sub> or other phosphonate halide, phosphate, phosphite halide, phosphite.

The present invention provides a method for preparation of the compound of formula II, comprising the step of esterifying the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with succinic anhydride to obtain the compound of formula II, or the step of phosphoric esterifying the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with POCl<sub>3</sub>, PCl<sub>3</sub>, phosphonate halide, phosphate, phosphite halide, or phosphite to obtain the compound of formula II.

The present invention provides a method for preparation of the compound of formula IIIa and IIIb, comprising the step of reacting the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with POCl<sub>3</sub> or other phosphonate halide, phosphate, phosphite and the like, or the step of reacting the first lead compound triptolide with POCl<sub>3</sub> or other phosphonate halide, phosphite halide and the like.

The present invention provides Use of the compounds of the present invention in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent. In an embodiment, the immunosuppressive agent or anti-inflammatory agent is used in the

treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2. In another embodiment, the diseases are autoimmune deficiency diseases and inflammatory diseases. In another embodiment, the diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Page 10, line 36, please amend the line to read:

73.5(C-14, d, J=22.8Hz), 123.2(3-C), 162.5(4-C), 173.2(20-C), 63.5, 64.5, 64.6(8-C, 9-C, 13-C).

AMENDMENT TO THE DRAWINGS


Figure1, and Figure 2, please amend all “ $\mu\text{g}$ ” to “ $\mu\text{M}$ ”.

REMARKS

Attached are the replacement pages for the above amendments.

Any additional fees required in connection with this communication which are not specifically provided for herewith are authorized to be charged to the Deposit Account No. 50-2638 in the name of Greenberg Traurig LLP. Any overpayments are also authorized to be credited to this account.

Respectfully submitted,




Charles Berman, Esq.  
Reg. No. 29,249

Date: 18 March 2005

**GREENBERG TRAURIG LLP** (CUSTOMER NUMBER 33717)  
2450 Colorado Ave., Suite 400E,  
Santa Monica, CA 90404  
Phone: (310) 586-7770/Fax: (310) 586-0271  
E-Mail: bermanc@gtlaw.com

LA-FS1\328778v01\58260.011600




II

wherein R<sub>1</sub> is H, alkyl having 1-4 carbon atom(s), -Ac, -C(=O)(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H (n is an integer of 1-4), phosphate ( $-\text{P}(\text{O})(\text{OX}_1)(\text{OX}_2)-$ ), or phosphite ( $-\text{P}(\text{H})(\text{OX}_1)(\text{OX}_2)-$ ), wherein X<sub>1</sub> and X<sub>2</sub> are Na, K, or NH<sub>4</sub>; and R<sub>2</sub> is H, -SCN, -Cl or -Br.

Preferably, R<sub>1</sub> is phosphate ( $-\text{P}(\text{O})(\text{OX}_1)(\text{OX}_2)-$ ), or


4-Oxo-butyrac succinic anhydride [-C(=O)(CH<sub>2</sub>)<sub>4</sub>CO<sub>2</sub>H], in which X<sub>1</sub> and X<sub>2</sub> are Na, R<sub>2</sub> is -SCN.

The third type of novel derivatives of triptolide is as follow:



IIIa


wherein R<sub>2</sub> is H, -SCN, -Cl or -Br.



IIIb

Another objective of the present invention is to provide the synthetic methods of these novel highly water-soluble derivatives of triptolide, and more particularly, the synthetic methods of preparing above three types of water-soluble derivatives of triptolide from the following two lead compounds (see Example 1-7 for details).


The first lead compound is triptolide:



**Triptolide(T)**

US Patent 5,962,516 discloses a method for the preparation of 14-succinyl triptolide and sodium salt thereof from triptolide. 14- $\beta$ -phosphate bisodium triptolide produced by phosphorylation according to the present invention, however, has higher water solubility.

The second lead compound is 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide:



**12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide (T-SCN)**

The present invention provides a method for preparation of the compound of formula I, comprising the step of reacting the first lead compound triptolide with  $\text{POCl}_3$ ,  $\text{PCl}_3$  or other phosphonate halide, phosphate, phosphite halide, phosphite.

The present invention provides a method for preparation of the compound of formula II, comprising the step of esterifying the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with succinic anhydride to obtain the compound of formula II, or the step of phosphoric esterifying the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with  $\text{POCl}_3$ ,  $\text{PCl}_3$ , phosphonate halide, phosphate, phosphite halide, or phosphite to obtain the compound of formula II.

The present invention provides a method for preparation of the compound of formula IIIa and IIIb, comprising the step of reacting the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with  $\text{POCl}_3$  or other phosphonate halide, phosphate, phosphite and the like, or the step of reacting the first lead compound triptolide with  $\text{POCl}_3$  or other phosphonate halide, phosphite halide and the like.

The present invention provides Use of the compounds of the present invention in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent. In an embodiment, the immunosuppressive agent or anti-inflammatory agent is used in the

5 treatment of diseases associated with growth of lymphocytes T and B cells; production of  
cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2. In another  
embodiment, the diseases are autoimmune deficiency diseases and inflammatory diseases.  
In another embodiment, the diseases are selected from the group consisted of rheumatoid  
10 arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis,  
atherosclerosis, type I diabetes, and nephritis.

10 Another objective of the present invention is to provide molecular biological  
evidence of immunosuppressive activity of these novel highly water-soluble derivatives  
of triptolide (Example 8, 9). It has been demonstrated these novel derivatives of triptolide  
significantly inhibit the production of cytokines such as IL-1, IL-2, IL-6, iNOS and Cox-  
2.

15 A further objective of the present invention is to provide animal experiment  
evidence of low toxicity of these novel highly water-soluble derivatives of triptolide  
(Example 10). The water-soluble derivatives of triptolide prepared from T-SCN  
according to present invention have a significantly decreased toxicity. For example, the  
toxicity of sodium 12- $\beta$ -thiocyano-triptolide-13- $\beta$ -14- $\alpha$ -phosphate with a LD<sub>50</sub> of 126  
20 mg/kg body weight is much lower than that of triptolide which has a LD<sub>50</sub> of 0.85 mg/kg  
body weight, while the former has a quite high immunosuppressive activity.

25 A still another objective of the present invention is to provide animal experiment  
evidence of treating autoimmune deficiency diseases with these novel highly water-  
soluble derivatives of triptolide. For example, the experiment of effect on DNCB-induced  
delayed hypersensitivity reaction of mice (Example 11) and anti-inflammatory test with  
cotton ball granulation in rat (Example 12) have demonstrated all of the novel WDY  
series derivatives of triptolide have significant immunosuppressive and anti-inflammatory  
activities.

### 30 Description of the Figures

Fig 1. Effect of water-soluble derivatives of triptolide according to the present  
invention on IL-2 (medium: blank control; PHA: lipopolysaccharide, CsA: Cyclosporine  
A).

35 Fig 2. Effect of water-soluble derivatives of triptolide according to the present  
invention on IL-1, IL-6 and iNOS (medium: blank control; PHA: lipopolysaccharide,  
CsA: Cyclosporine A).


40 Fig 3. Effect of water-soluble derivatives of triptolide according to the present  
invention on PGE<sub>2</sub> content of HT-29 cell (pg/ml) (control = 22.93 pg/ml, indomethacin  
(indo) = 1.3 pg/ml, WDY 4 = 4.22 pg/ml, WDY 7 = 4.97 pg/ml).

Fig 4. The results of the effect of WDY 6 on contralateral paw.

Fig 5. The results of the effect of WDY 7 on contralateral paw.

Fig 6. The results of the effect of orally administrating WDY7 on the thickness of  
left paw.

**Example 4. Preparation of sodium triptolide-14- $\beta$ -phosphite (WDY 4)**



Under the protection of nitrogen atmosphere, 200 mg triptolide (0.556 mmol) and 20 ml pyridine were added into a three-necked bottle of 25ml, whereafter 0.10 ml  $\text{PCl}_3$  (1.149 mmol) was slowly dropwise added. Upon feeding, nitrogen gas was stopped to enter the three-necked bottle. After reacting for 1 hour under sealing, the reaction bottle was cooled down in ice bath. Then saturated aqueous  $\text{NaHCO}_3$  was slowly added to the reaction mixture to conduct hydrolytic reaction and neutralize to pH=9. The solvent in the mixture was vaporized to dryness under reduced pressure, and the residue was dissolved in chloroform/methanol (5/2) and the inorganic salts therein were removed. TLC detection was conducted by developing with n-butanol: water: glacial acetic acid (4:1:1), and major point was product WDY4 comprising a little other by-products. The product WDY4 was purified by H silica gel column chromatography using chloroform/methanol (5/2). The product was detected by TLC. The WDY4 was pooled, concentrated under reduced pressure to remove the solvent, dissolved in eluent and precipitated with ether to obtain purified product (yield 70 mg, 50%).  $R_f=0.46$ . Purple-red in developing reagent (Kedde's reagent). Water solubility >100 mg/ml.

IR(KBr) $\text{cm}^{-1}$ : 3424, 2965, 2365, 1750, 1627, 1226, 1028, 972.

$^1\text{H}$ NMR,  $\delta$ ppm: 0.74(3H, d,  $J=7.2\text{Hz}$ , 16- $\text{CH}_3$ ), 0.90(3H, d,  $J=6.8\text{Hz}$ , 17- $\text{CH}_3$ ), 0.94(3H, s, 18- $\text{CH}_3$ ), 1.25(1H, m, 1- $\alpha\text{H}$ ), 1.32(1H, m, 1- $\beta\text{H}$ ), 1.80(1H, t,  $J=14.2\text{Hz}$ , 6- $\beta\text{H}$ ), 1.94(1H, m, 2-H), 2.10(1H, m, 2-H), 2.20(1H, m, 6- $\alpha\text{H}$ ), 2.33(1H, m, 15-H), 2.59(1H, m, 5-H), 3.29(1H, m, 7-H), 3.52(1H, d,  $J=3.2\text{Hz}$ , 11-H), 3.82(1H, d,  $J=3.2\text{Hz}$ , 12-H), 4.03(1H, d,  $J=12.4\text{Hz}$ , 14-H), 4.83(2H, m, 19-H), 6.7(1H, d,  $J=595.6\text{Hz}$ , P-H).

$^{13}\text{C}$ NMR,  $\delta$ ppm: 13.9(18-C), 16.7(2-C), 17.0(16-C), 17.5(17-C), 22.8(6-C), 26.3(15-C), 29.2(1-C), 35.3(10-C), 40.1(5-C), 54.3(12-C), 54.9(11-C), 60.4(7-C), 70.3(19-C), 73.5(C-14, d,  $J=22.8\text{Hz}$ ), 123.2(3-C), 162.5(4-C), 173.2(20-C), 63.5, 64.5, 64.6(8-C, 9-C, 13-C).

$^{31}\text{P}$ NMR,  $\delta$ ppm: 1.34(d,  $J_{\text{P-H}}=599\text{Hz}$ ).

## II


wherein  $R_1$  is H, alkyl having 1-4 carbon atom(s),  $-C(=O)(CH_2)_nCO_2H-$ , wherein  $n$  is an integer of 1-4, or

phosphate ( $-\overset{\overset{O}{\parallel}}{P}<\overset{OX_1}{\underset{OX_2}{\phantom{H}}}$ ), or phosphite ( $-\overset{\overset{O}{\parallel}}{P}<\overset{OX_1}{\underset{H}{\phantom{H}}}$ ),

wherein  $X_1$  and  $X_2$  are Na, K, or  $NH_4$ ; and  $R_2$  is H, -SCN, -Cl or -Br.

4. A method for preparation of the compound according to claim 3, comprising the step of esterifying ~~or phosphoric esterifying~~ the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with succinic anhydride to obtain the compound of formula II, or the step of phosphoric esterifying the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with  $POCl_3$ ,  $PCl_3$ , phosphonate halide, phosphate, phosphite halide, or phosphite to obtain the compound of formula II.

5. A triptolide derivative of formula IIIa or IIIb



Wherein  $R_2$  is H, SCN, Cl or Br.

6. A method for preparation of the compound according to claim 5, comprising the step of reacting the second lead compound 12- $\beta$ -thiocyano-13- $\alpha$ -hydroxy triptolide with  $POCl_3$  or other phosphonate halide, phosphate, phosphite and the like, or the step of reacting the first lead compound triptolide with  $POCl_3$  or other phosphonate halide, phosphite halide and the like.

7. Use of the compounds according to any one of claims 1, 3, and 5 in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.